Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
Petri dish with cultured cells in a dimly lit lab

Jul 10, 2026

Insilico Medicine to Present Longevity and AI Drug Innovations at BIO Asia-Taiwan 2026

Insilico Medicine is poised to make a significant impact at BIO Asia-Taiwan 2026, where CEO Dr. Alex Zhavoronkov will deliver a keynote on the intersection of longevity science and artificial intelligence. Scheduled for July 15, his presentation will explore how these disciplines can transform drug discovery and enhance company scalability.The conference, running from July 15 to 19 at the Taipei Nangang Exhibition Center, will feature over 850 exhibitors from nearly 60 countries, focusing on adv
A minimalist illustration of a pill on a dark background, symbolizing an oral medication.

Jul 10, 2026

Chinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RA

Chinese biotech MindRank has successfully secured $52 million to enhance its AI-driven pipeline, focusing on an oral GLP-1 receptor agonist currently in Phase III trials in China.Based in Hangzhou, MindRank utilizes its innovative Molecule Arts Platform (MAP), which integrates computational methods, experimental data, and clinical insights to streamline drug discovery. This funding will support the development of its lead candidate, MDR-001, aimed at treating obesity and type 2 diabetes. The com
A test tube in a dimly lit lab, symbolizing antibody research.

Jul 9, 2026

Alchemab Raises £25 Million Extension to Series A to Advance AI-Driven Antibody Pipeline

Alchemab Therapeutics has successfully secured a £25 million extension to its Series A funding, bringing its total to £109 million, marking a significant milestone as the largest life sciences investment from the British Business Bank to date.This new capital will facilitate the growth of Alchemab's clinical pipeline and expand its proprietary antibody database from 500 million to over one billion sequences. The company employs its AI-driven Resiliome™ platform to discover naturally occurring pr
A minimalist representation of a drug compound in flat design.

Jul 9, 2026

AI in pharma market to hit $28.6b by 2034 on drug discovery push

The global market for artificial intelligence in pharmaceuticals is projected to reach $28.63 billion by 2034, primarily fueled by advancements in drug discovery processes.According to a report by Polaris Market Research, AI is increasingly integral to various stages of drug discovery, including identifying drug targets, analyzing protein structures, and simulating chemical interactions, which surpasses traditional laboratory methods. The financial implications of this shift are substantial, as
A minimalist illustration of a lung and a pill in a dark color scheme.

Jul 9, 2026

Insilico Medicine Advances AI-Discovered IPF Drug Rentosertib into Phase III Trial

Insilico Medicine has announced the progression of its AI-discovered drug, Rentosertib, into Phase III trials, marking a significant advancement in the treatment of idiopathic pulmonary fibrosis (IPF).This oral TNIK inhibitor, identified through Insilico’s Pharma.AI platform, aims to address the high unmet medical needs associated with IPF, a progressive lung disease characterized by scarring that severely affects respiratory function. The Phase IIa study demonstrated promising results, showing
A molecular model and research notebook in a dimly lit lab

Jul 8, 2026

Aureka offers open-source AI module for drug discovery

Aureka has introduced an innovative open-source AI tool aimed at transforming drug discovery processes. Named the Open Drug Discovery Engine (OpenDDE), this foundational model is designed to enhance structural reasoning in drug development, making advanced biomolecular studies more accessible to a wider range of researchers and organizations.Unlike many proprietary AI systems in the drug discovery field, which come with significant costs, Aureka's OpenDDE is open-source, allowing for broader use
Pill bottle of Rentosertib on a wooden table at a clinical trial site

Jul 8, 2026

Insilico Medicine launches Phase III trial of AI-designed Rentosertib drug

Insilico Medicine has launched a Phase III clinical trial for Rentosertib, an innovative oral TNIK inhibitor aimed at treating idiopathic pulmonary fibrosis (IPF), utilizing its advanced Pharma.AI platform for drug discovery.The trial marks a significant milestone for Insilico Medicine, as Rentosertib—previously referred to as ISM001-055 / INS018_055—targets TNIK, a protein linked to fibrosis and inflammation. This drug was developed through a combination of Insilico's PandaOmics biology engine
Open pill bottle with capsules on a lab countertop

Jul 8, 2026

MindRank Secures $52M Series B Financing, AI-Developed Weight-Loss Drug Advances to Phase 3 Clinical Trials | 36Kr Exclusive

MindRank AI has successfully raised $52 million in Series B funding to enhance its AI-driven drug discovery capabilities, particularly focusing on its oral GLP-1 small molecule, MDR-001, which is now advancing to Phase III clinical trials.The financing round attracted prominent investors and will be allocated to further develop MindRank's Molecule Arts Platform (MAP), which integrates advanced AI technologies to streamline the drug discovery process. The platform employs a three-tier architectur
A vial of drug compound on a lab bench with chemical reagents in the background.

Jul 7, 2026

Nvidia Powers AI Agent Strategies for Certara, Silo Pharma - NVIDIA (NASDAQ:NVDA)

Nvidia is enhancing AI capabilities in drug development through collaborations with Certara and Silo Pharma.Certara has announced its integration of Nvidia’s BioNeMo Agent Toolkit into its AI-driven drug development platform. This partnership aims to leverage Certara's scientific software and regulatory expertise alongside Nvidia's advanced AI frameworks. The BioNeMo toolkit will enable AI agents to operate as autonomous researchers, enhancing Certara's biosimulation models and supporting variou
A minimalist representation of a peptide molecule in a dark color scheme.

Jul 7, 2026

LG AI, D&D Pharmatech push AI-powered peptide drug discovery

The partnership between LG AI Research and D&D Pharmatech marks a significant step forward in the use of artificial intelligence for peptide drug discovery, particularly in addressing hard-to-treat diseases.As South Korea's peptide market continues to expand, projected to reach $3.25 billion by 2033, the collaboration aims to leverage AI to innovate in therapeutic development. LG AI Research's advanced AI models will analyze disease target structures and propose novel peptide sequences, streamli
A minimalist representation of protein structure and molecular docking in flat design.

Jul 7, 2026

Certara accelerates drug discovery with Nvidia BioNeMo toolkit as AI reshapes pharma R&D

Nvidia's introduction of the BioNeMo Agent Toolkit is set to revolutionize the landscape of drug discovery, enabling AI to autonomously manage intricate scientific processes.The BioNeMo toolkit, launched at the BIO International Convention, synthesizes over a decade of Nvidia's advancements in life sciences into a suite that transforms biomolecular models into callable skills. This allows AI agents to undertake complex tasks such as protein structure predictions and molecular docking without dir
A vial of a drug compound on a lab bench in a dimly lit laboratory.

Jul 7, 2026

$7 Billion Into AI Drug Discovery and Zero Approved Drugs: The Industry Is Funding the Wrong Race

The biopharmaceutical industry is facing a paradox as it invests over $7 billion into AI-driven drug discovery while achieving zero approved drugs from these efforts. This discrepancy highlights the challenges of translating AI advancements into viable clinical outcomes.Since January 2026, major pharmaceutical companies have poured substantial resources into AI drug discovery, partnering with firms like Insilico Medicine. Despite these investments, the reality remains stark: no AI-discovered dru